MX2012000129A - Expresion de las cadenas ligeras sustitutas. - Google Patents

Expresion de las cadenas ligeras sustitutas.

Info

Publication number
MX2012000129A
MX2012000129A MX2012000129A MX2012000129A MX2012000129A MX 2012000129 A MX2012000129 A MX 2012000129A MX 2012000129 A MX2012000129 A MX 2012000129A MX 2012000129 A MX2012000129 A MX 2012000129A MX 2012000129 A MX2012000129 A MX 2012000129A
Authority
MX
Mexico
Prior art keywords
surrogate light
expression
light chains
light chain
surrogate
Prior art date
Application number
MX2012000129A
Other languages
English (en)
Spanish (es)
Inventor
Lawrence Horowitz
Ramesh R Bhatt
Original Assignee
Sea Lane Biotechnologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sea Lane Biotechnologies Llc filed Critical Sea Lane Biotechnologies Llc
Publication of MX2012000129A publication Critical patent/MX2012000129A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Holo Graphy (AREA)
MX2012000129A 2009-06-26 2010-06-25 Expresion de las cadenas ligeras sustitutas. MX2012000129A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22087809P 2009-06-26 2009-06-26
PCT/US2010/040052 WO2010151808A1 (en) 2009-06-26 2010-06-25 Expression of surrogate light chains

Publications (1)

Publication Number Publication Date
MX2012000129A true MX2012000129A (es) 2012-02-01

Family

ID=42563044

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000129A MX2012000129A (es) 2009-06-26 2010-06-25 Expresion de las cadenas ligeras sustitutas.

Country Status (12)

Country Link
US (1) US8969082B2 (enExample)
EP (2) EP3205723A1 (enExample)
JP (2) JP2012531208A (enExample)
KR (2) KR20180017231A (enExample)
CN (1) CN102498210B (enExample)
AU (1) AU2010265949B2 (enExample)
BR (1) BRPI1015916A2 (enExample)
CA (1) CA2764729C (enExample)
IL (1) IL216796A (enExample)
MX (1) MX2012000129A (enExample)
TW (1) TWI560271B (enExample)
WO (1) WO2010151808A1 (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2132312B1 (en) 2007-03-27 2016-01-27 Sea Lane Biotechnologies,llc. Constructs and libraries comprising antibody surrogate light chain sequences
CA2761681A1 (en) 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
EP3028565B1 (en) 2009-07-08 2017-09-27 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2806252C (en) 2010-07-29 2019-05-14 Xencor, Inc. Antibodies with modified isoelectric points
WO2013003652A1 (en) 2011-06-28 2013-01-03 Sea Lane Biotechnologies, Llc Multispecific stacked variable domain binding proteins
EP2736928B1 (en) 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Sur-binding proteins against erbb3
EP2757875B2 (en) 2011-09-19 2023-03-22 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
WO2013045916A1 (en) * 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
WO2013096828A1 (en) 2011-12-22 2013-06-27 Sea Lane Biotechnologies, Llc Surrogate binding proteins
WO2013109994A1 (en) 2012-01-20 2013-07-25 Sea Lane Biotechnologies, Llc Surrobody cojugates
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
HRP20191865T1 (hr) 2013-01-14 2020-01-10 Xencor, Inc. Novi heterodimerni proteini
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
CA3093606A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Heterodimeric proteins for induction of t cells
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US20150033372A1 (en) * 2013-05-01 2015-01-29 Kymab Limited Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
EP3954713A3 (en) 2014-03-28 2022-03-30 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3223907A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
CN116333153A (zh) 2014-11-26 2023-06-27 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
CA2971186A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
US11253546B2 (en) 2014-12-15 2022-02-22 The Regents Of The University Of California Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
JP2018507254A (ja) * 2015-02-02 2018-03-15 アイツー ファーマシューティカルズ， インコーポレーテッド 抗代替軽鎖抗体
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
KR20180085800A (ko) 2015-12-07 2018-07-27 젠코어 인코포레이티드 Cd3 및 psma에 결합하는 이종이합체성 항체
IL263542B2 (en) 2016-06-14 2024-10-01 Xencor Inc Bispecific antibodies inhibit immunological checkpoint
KR20190020341A (ko) 2016-06-28 2019-02-28 젠코어 인코포레이티드 소마토스타틴 수용체 2에 결합하는 이종이량체 항체
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP2019530440A (ja) 2016-09-02 2019-10-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物
CN110214148A (zh) 2016-10-14 2019-09-06 Xencor股份有限公司 含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
MX2020006322A (es) 2017-12-19 2020-09-18 Xencor Inc Proteinas de fusion il-2 fc modificadas.
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
AU2019256539A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
EP3781598A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
AU2020232605A1 (en) 2019-03-01 2021-10-21 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
KR102607909B1 (ko) 2020-08-19 2023-12-01 젠코어 인코포레이티드 항-cd28 조성물
WO2022177918A1 (en) 2021-02-16 2022-08-25 Children's Health Care D/B/A Children's Minnesota Methods for treating b-all by administering a pre-bcr complex antagonist
JP2024511319A (ja) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS60222842A (ja) 1984-04-19 1985-11-07 Fuji Photo Film Co Ltd ハロゲン化銀写真乳剤およびその製造方法
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5182205A (en) 1986-11-27 1993-01-26 Hoffmann-La Roche Inc. Nucleotide sequences which are selectively expressed in pre-B cells and probes therefor
EP0269127B1 (en) 1986-11-27 1994-02-23 F. Hoffmann-La Roche Ag Nucleotide sequences which are selectively expressed in pre-B cells and probes therefor
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
WO2000052153A2 (en) 1999-03-02 2000-09-08 Maxygen, Inc. Method to identify ligands for orphan receptors
US20030215453A1 (en) * 2002-05-14 2003-11-20 Dedera Douglas A. Methods of therapy and diagnosis using immunotargeting of cells expressing VpreB1 protein
EP1265918A1 (en) 2000-03-15 2002-12-18 Incyte Genomics, Inc. Human immune response proteins
US20060147997A1 (en) * 2004-11-30 2006-07-06 Virosys Pharmaceuticals, Inc. PenetraBodies: receptor-mediated targeted delivery of functionally-active human antibody fragments into cytosol for the treatment of chronic infections and diseases
EP2132312B1 (en) 2007-03-27 2016-01-27 Sea Lane Biotechnologies,llc. Constructs and libraries comprising antibody surrogate light chain sequences
WO2010006286A2 (en) 2008-07-11 2010-01-14 Sea Lane Biotechnologies, Llc Constructs and libraries comprising antibody surrogate kappa light chain sequences

Also Published As

Publication number Publication date
IL216796A0 (en) 2012-02-29
TW201107468A (en) 2011-03-01
EP2446032B8 (en) 2017-03-15
CA2764729A1 (en) 2010-12-29
TWI560271B (en) 2016-12-01
BRPI1015916A2 (pt) 2015-09-01
CA2764729C (en) 2019-04-02
EP2446032B1 (en) 2016-12-21
EP3205723A1 (en) 2017-08-16
JP2012531208A (ja) 2012-12-10
WO2010151808A1 (en) 2010-12-29
KR20120095343A (ko) 2012-08-28
CN102498210A (zh) 2012-06-13
KR101829073B1 (ko) 2018-02-13
US8969082B2 (en) 2015-03-03
AU2010265949B2 (en) 2016-05-05
KR20180017231A (ko) 2018-02-20
AU2010265949A1 (en) 2011-12-22
JP2016105714A (ja) 2016-06-16
CN102498210B (zh) 2015-07-29
US20100330676A1 (en) 2010-12-30
IL216796A (en) 2015-09-24
EP2446032A1 (en) 2012-05-02

Similar Documents

Publication Publication Date Title
MX2012000129A (es) Expresion de las cadenas ligeras sustitutas.
IN2011KN03851A (enExample)
BRPI0918648A2 (pt) anticorpos multiespecíficos
MX2012011496A (es) Cuerpos de guias de onda opticos con alta intensidad luminosa y alta transparencia.
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
ZA201202545B (en) Light source
GB0907947D0 (en) Light source
GB0908727D0 (en) Light source
GB2476926B (en) Tuneable quantum light source
PL2342592T3 (pl) Źródło światła
EA201391563A1 (ru) Твердое вещество полихлоропрен с тиксотропными свойствами
IN2012DN01846A (enExample)
TWI365476B (en) Apparatus of flat light source with dual-side emitting light
GB2469821B (en) Improved light source
TN2011000486A1 (en) Fertilization modulation compounds and process for implementing them
EP2416034A4 (en) SILENT CHAIN TRANSMISSION
PA8849101A1 (es) Procedimiento de preparación del hemifumarato de eplivanserina
AU323000S (en) Light Fitting FG100
UA50484U (ru) Полиуретан с фрагментами изоникотинилгидразон-d-лактозы
CL2009001216S1 (es) Perfil.
HU3843U (en) L.e.d. light source
CL2009000992S1 (es) Envase.
AU323499S (en) Wood bucket
AU313101S (en) Glass balustrading clamp - Frameless
HK1194761A (en) Chimaeric surrogate light chains (slc) comprising human vpreb

Legal Events

Date Code Title Description
FG Grant or registration